Adjunct Full Professor

Cannon Research Center

Email:

Education:

Professional Experience:

Research Interests:

• The liver in health and disease, including inherited and acquired disorders of porphyrin, heme, and iron metabolism.
• Drug-induced liver injury-mechanisms, pathogenesis, recognition, and management
• Viral hepatitis and its management
• Alcoholic liver disease
• Non-alcoholic fatty liver disease

Courses Taught:

• Biol8200: Interdisciplinary Colloquium - UNCC
• Seminars in Clinical and Translational Research - CHS
• Cannon Summer Scholars Program - CHS

Publications:

Kohlroser J, Mathai J, Reichheld J, Banner BF, and Bonkovsky HL. Hepatotoxicity due to troglitazone: report of two cases and review of adverse events reported to the United States Food and Drug Administration. American Journal of Gastroenterology 95: 272-276, 2000.

Lu TH, Shan Y, Pepe J, Lambrecht RW and Bonkovsky HL. Upstream regulatory elements in chick heme oxygenase-1 promoter: a study in primary cultures of chick embryo liver cells. Molecular and Cellular Biochemistry 209: 17-27, 2000.

Bonkovsky HL and Lambrecht RW. Iron-induced liver injury. Clinics in Liver Disease 4: 409-429, 2000.

Shan Y, Pepe J, Lu TH, Elbirt KK, Lambrecht RW, and Bonkovsky HL. Induction of the heme oxygenase-1 gene by metalloporphyrins. Arch. Biochem. Biophys. 380: 219-227, 2000.

Fontana RJ, Israel J, LeClair P, Banner BF, Tortorelli K, Grace N, Levine RA, Fiarman G, Thiim M, Tavill AS, and Bonkovsky HL. Iron reduction before and during interferon therapy of chronic hepatitis C: results of a multicenter, randomized, controlled trial. Hepatology 31: 730-736, 2000 [PMID: 10706565].

Di Bisceglie AM, Bonkovsky HL, Chopra S, Flamm S, Reddy RK, Grace N, Killenberg P, Hunt C, Tamburro C, Tavill AS, Ferguson R, Krawitt E, Banner B, and Bacon BR. Iron reduction as an adjuvant to interferon therapy in patients with chronic hepatitis C who have previously not responded to interferon: a multi-center, prospective, randomized, controlled trial. Hepatology 32: 135-138, 2000. [PMID 10869301].

Childs S, Weintstein BM, Mohideen MA, Donohue S, Bonkovsky HL, and Fishman MC. Zebrafish dracula encodes ferrochelatase and its mutation provides a model for erythropoietic protoporphyria. Current Biology 10: 1001-1004, 2000. [PMID: 10985389]

Szabo G, Katz E, and Bonkovsky HL. Management of recurrent hepatitis C after liver transplantation: a concise review. Amer J Gastroent 95: 2164-2170, 2000. [PMID: 11007212]

Banner BF, Savas L, Zivny J, Tortorelli K, and Bonkovsky HL. Ubiquitin as a marker of cell injury in non-alcoholic steatohepatitis. American Journal of Clinical Pathology 114: 860-866, 2000.

Bonkovsky HL and Barnard GF. The porphyrias. Current Treatment Options in Gastroenterology 3: 487-499, 2000.

Bonkovsky HL and Mehta S. Hepatitis C: a review and update. Journal of the American Academy of Dermatology 44: 159-179, 2001.

Fernandez M, Lambrecht RW, and Bonkovsky HL. Increased heme oxygenase activity in splanchnic organs from portal hypertensive rats: role in modulating mesenteric vascular reactivity. Journal of Hepatology 34: 812-817, 2001 [PMID: 11451163].

Bonkovsky HL, Stefancyk D, Tortorelli K, Banner BF, Liu Q, Zucker G, Israel J, Stagias J, and Colker J. Comparative effects of different doses of ribavirin plus interferon alpha-2b for therapy of chronic hepatitis C: results of a controlled, randomized trial. Dig. Diseases & Sciences, 46: 2051-2059, 2001.

Mehta S, Levey JM, and Bonkovsky HL. Extrahepatic manifestations of infection with hepatitis C virus. Clin. Liver Disease 5: 979-1008, 2001 [PMID: 11685805] [PMID: 11685805].

Gildemeister OS, Pepe JA, Lambrecht RW, and Bonkovsky HL. Induction of heme oxygenase-1 by phenylarsine oxide: studies in cultured primary liver cells. Molecular and Cellular Biochemistry 226: 17-26, 2001.

Tian W, Bonkovsky HL, Shibahara S, and Cohen DM. Urea and hypertonicity increase expression of heme oxygenase-1 in murine renal medullary cells. Amer. J. Physiol. Renal Physiol. 281: F983-F991, 2001.

Bonkovsky HL. Iron as a comorbid factor in chronic viral hepatitis. Amer. J. Gastroenterol. 97: 1-4, 2002.

Lambrecht RW and Bonkovsky HL. Hemochromatosis and porphyria. Seminars Gastroint. Dis. 13: 109-119, 2002.

Shan Y, Pepe J, Lambrecht RW, and Bonkovsky HL. Mapping of the chick heme oxygenase-1 proximal promoter for responsiveness to metalloporphyrins. Arch. Biochem. Biophys. 399: 159-166, 2002. [PMID: 11888201]

Bonkovsky HL. Congenital erythropoietic porphyria. Handbook of Rare Disorders, National Organization of Rare Disorders, 2002.

Rolfs A, Bonkovsky HL, Kohlroser JG, McNeal K, Berger UV, and Hediger MA. Intestinal expression of genes involved in iron absorption in humans. Amer. J. Physiol.. Gastrointest. Liver Physiol. 282: G598-G607, 2002 [PMID: 11897618].

Bonkovsky HL, Azar R, Bird S, Szabo G, and Banner B. Severe cholestatic hepatitis caused by thiazolidinediones—risks associated with substituting rosiglitazone for troglitazone. Dig. Dis. & Sci. 47: 1632-1637, 2002 [PMID: 12141828].

Bonkovsky HL. Beware of iron overload. Bottom Line Health 16 (9): 7-9, Sept. 2002.

Agrawal S and Bonkovsky HL. Management of nonalcoholic steatohepatitis: an analytic review. J. Clin. Gastroenterology 35: 253-261, 2002 [PMID: 12192203].

Do KD, Banner BF, Katz E, Szymanski IO, and Bonkovsky HL. Benefits of chronic plasmapheresis and intravenous heme-albumin in erythropoietic protoporphyria after liver transplantation. Transplantation 73: 469-472, 2002 [PMID: 11884947].

Bonkovsky HL, Troy N, McNeal K, Banner BF, Sharma A, Obando J, Mehta S, Koff RS, Liu Q, Hsieh CC. Iron and HFE or TfR1 mutations as comorbid factors for development and progression of chronic hepatitis C. J. Hepatol. 37: 848-854, 2002.

Bonkovsky HL. Hepatic manifestations of systemic disease. Clin. Liver Dis. 6: 1-2, 2002.

Bonkovsky HL. Optimal management of non-alcoholic fatty liver/steatohepatitis. J. Clin. Gastroenterol. 36: 193-195, 2003 [PMID: 12590226].

Bonkovsky HL, Lambrecht RW, and Shan Y. Iron as a co-morbid factor in non-hemochromatotic liver disease. Alcohol 30: 137-144, 2003. [PMID: 12957298]

Fernandez M and Bonkovsky HL. Vascular endothelial growth factor increases heme oxygenase-1 protein expression in the chick embryo chorioallantoic membrane. Brit. J. Pharmacol. 139: 634-640, 2003.

Shiffman ML, Di Bisceglie A, Lindsay KL, Morishima C, Wright EC, Everson G, Lok A, Morgan T, Bonkovsky HL, Lee W, Dienstag J, Ghany M, and Everhart J. PEG interferon alfa-2a in patients with chronic hepatitis C who have failed prior treatment with interferon or interferon and ribavirin: (Publication # 1 from the HALT-C Trial Group). Gastroenterology 126: 1015-1023, 2004. Discussion, 947 [PMID 15057741].

Chemmanur AT and Bonkovsky HL. The hepatic porphyrias: diagnosis and management. Clinics in Liver Disease 8: 807-838, 2004 [PMID: 15464657].

Shan Y, Lambrecht RW, Bonkovsky HL. Identification of key elements that are responsible for heme-mediated induction of the avian heme oxygenase-1 gene. Biochimica et Biophysica Acta 1679: 87-94, 2004. [PMID: 15297142]

Lee WM, Bonkovsky HL, Di Bisceglie A, Dienstag J, Everson GT, Ghany M, Morgan T, Lindsay KL, Lok A, Shiffman M, Gretch D, Wright EC, Everhart J, and the HALT-C Trial Group. Evolution of the HALT-C trial: pegylated interferon as maintenance therapy for patients with chronic hepatitis C in previous interferon nonresponders. (Publication # 4 from the HALT-C Trial Group) Controlled Clinical Trials 25: 472-492, 2004 [PMID 15465617].

Shan Y, Lambrecht RW, Ghaziani T, Donohue SE, and Bonkovsky HL. Role of Bach-1 in regulation of heme oxygenase-1 in human liver cells: insights from studies with small interfering RNAs. J. Biol. Chem. 279: 51,769-51,774, 2004 [PMID: 15465821].

Sendi H, Ghaziani T, Zali MR, Adibi P, Agah MR, Jazayeri M, Shahraz S, Magnius L, and Bonkovsky HL. Hemochromatosis mutations in Iranians with hepatitis B virus infection. Clinical Infectious Diseases 40: e19-e21, Epub 2004, Dec 29 [PMID: 15668853].

Rothman AL, Morishima C, Bonkovsky HL, Polyak SJ, Ray R, Di Bisceglie AM, Lindsay KL, Malet PF, Chang M, Gretch DR, Sullivan DG, Bhan AK, Wright EC, Koziel MJ, and the HALT-C Trial Group. Associations among clinical, histologic, immunologic, and viral quasispecies measures in advanced chronic hepatitis C: baseline analysis of the HALT-C Trial. (Publication # 3 from the HALT-C Trial Group). Hepatology 41: 617-624, 2005 [PMID: 15726656].

Anderson KE, Bloomer JR, Bonkovsky HL, Kushner JP, Pierach CA, Pimstone NR, and Desnick RJ. Recommendations for the diagnosis and treatment of the acute porphyrias. Ann Int Med 142: 439-450, 2005 [PMID: 15767622].

Polyak SJ, Sullivan DG, Austin MA, Dai JY, Shuhart MC, Lindsay KL, Bonkovsky HL, Di Bisceglie AM, Lee WM, Morishima C, Gretch DR and The HALT-C Trial Group. Comparison of amplification enzymes for hepatitis C virus quasispecies analysis. (Publication # 9 from the HALT-C Trial Group) Virology Journal 2: 41-46, 2005 [PMID: 15847697].

Siddiqui J, Jaffe PE, Aziz K, Forouhar F, Sheppard R, Covault J, and Bonkovsky HL. Fatal air and bile embolism after percutaneous liver biopsy and ERCP. Gastrointestinal Endoscopy 61: 153-157, 2005 [PMID: 15672079].

Di Bisceglie AM, Sterling RK, Chung RT, Everhart JE, Dienstag JL, Bonkovsky HL, Wright EC, Everson GT, Lindsay KL, Lok ASF, Lee WM, Morgan TR, Ghany MG, Gretch DR, and the HALT-C Trial Group. Serum alpha-fetoprotein levels in patients with advanced hepatitis C: results from the HALT-C Trial. (Publication # 7 from the HALT-C Trial Group) J Hepatol 43: 434-441, 2005 [PMID: 16136646].

Lok ASF, Ghany MG, Goodman ZD, Wright EC, Everson GT, Sterling RK, Everhart JE, Lindsay KL, Bonkovsky HL, Di Bisceglie AM, Lee WM, Morgan TR, Dienstag JL, Morishima C, and the HALT-C Trial Group. Predicting cirrhosis in patients with hepatitis C based on standard laboratory tests: results of the HALT-C cohort. (Publication# 6 from the HALT-C Trial Group) Hepatology 42: 282-292, 2005 [PMID: 15986415].

Giuggio VM, Bonkovsky HL, and Rothman AL. Evolution of the intrahepatic T cell repertoire during chronic hepatitis C virus infection. Viral Immunology 18: 179-189, 2005 [PMID: 15802962].

Shan Y, Lambrecht RW, and Bonkovsky HL. Association of HCV infection with serum iron status: analysis of data from NHANES III. Clin. Inf. Dis. 40: 834-841, 2005 [PMID: 15736017].

Kolluri S, Sadlon TJ, May BK, and Bonkovsky HL. Haem repression of the housekeeping 5-aminolaevulinic acid synthase gene in the hepatoma cell line LMH. Biochem J 392 (Pt 1): 173-180, 2005 [PMID: 16033334].

Alla V and Bonkovsky HL. Iron in non-hemochromatotic liver disorders. Semin Liver Disease 25: 461-472, 2005 [PMID: 16315139].

Morishima C, Polyak SJ, Ray R, Doherty MC, Di Bisceglie A, Malet PF, Bonkovsky HL, Sullivan DG, Gretch DR, Rothman AL, Koziel MJ, Lindsay KL, and the HALT-C Trial Group. Hepatitis C virus-specific immunity and quasispecies variability at baseline are associated with non-response to antiviral therapy during advanced hepatitis C. (Publication # 11 from the HALT-C Trial Group). The Journal of Infectious Diseases, 193:931-940, 2006 [PMID: 16518754].

Fontana RJ, Bielauskas LA, Back-Madruga C, Lindsay KL, Kronfol Z, Lok AS, Padmanabhan L, and the HALT-C Trial Group. Cognitive function in hepatitis C patients with advanced fibrosis enrolled in the HALT-C Trial. (Publication # 5 from the HALT-C Trial Group). J. Hepatology 43: 614-622, 2005 [PMID: 16237784].

Fontana RJ, Di Bisceglie AM, Sanyal AJ, Mehta S, Doherty MC, Everson GT, Kahn JA, Malet PF, Sheikh MY, Chung R, Ghany MG, Gretch DR, Everhart JE, and the HALT-C Trial Group. Portal hypertensive gastropathy in chronic hepatitis C patients with bridging fibrosis and compensated cirrhosis: results from the HALT-C Trial. (Publication # 12 from the HALT-C Trial Group). Amer J Gastroenterology 101: 983-992, 2006.

Bonkovsky HL. Hepatotoxicity associated with supplements containing Chinese green tea (Camellia sinensis). Annals of Internal Medicine 144: 68-71, 2006 [PMID: 16389263].

Bonkovsky HL. Neurovisceral porphyrias: what a hematologist needs to know. Hematology 2005, The American Society of Hematology Education Program Book, The American Society of Hematology, Washington, D.C., pp. 24-30, 2005.

McGuire BM, Bonkovsky HL, Carithers RL, Jr., Chung RT, Goldstein LI, Lake JR, Lok AS, Potter CJ, Rand E, Voigt MD, Davis PR, and Bloomer JR. Liver transplantation for erythropoietic protoporphyria liver disease. Liver Transplantation 11:1590-1596, 2005 [PMID: 16315313].

Ghaziani T, Shan Y, Lambrecht RW, Donohue S, Pietschman T, Bartenschlager R, and Bonkovsky HL. HCV proteins increase expression of heme oxygenase-1 and decrease expression of Bach1 in human hepatoma cells. Journal of Hepatology, 45:5-12, 2006. [PMID 16530877]

Bonkovsky HL. Iron metabolism and hereditary hemochromatosis. Czech and Slovak Journal of Gastroenterology and Hepatology, Supplement, 2006.

Alla V, Abraham J, Siddiqui J, Raina D, Wu GY, Chalasani NP, and Bonkovsky HL. Autoimmune hepatitis triggered by statins. J. Clin. Gastroenterol. 40: 757-761, 2006. [PMID 16940892]

Morishima C, Morgan TR, Everhart JE, Wright EC, Shiffman ML, Everson GT, Lindsay KL, Lok ASF, Bonkovsky HL, Di Bisceglie AM, Lee WM, Dienstag JL, Ghany MG, Gretch DR, HALT-C Trial Group. HCV RNA detection by TMA during the hepatitis C antiviral long-term treatment against cirrhosis (HALT-C) trial. (Publication # 16 from the HALT-C Trial Group). Hepatology 44: 360-367, 2006. [PMID: 16871570]

Bonkovsky HL, Naishadham D, Lambrecht RW, Chung RT, Hoefs JC, Nash SR, Rogers TE, Banner BF, Sterling RK, Donovan JA, Fontana RJ, Di Bisceglie AM, Ghany M, Morishima C, and the HALT-C Trial Group. Influence of iron and HFE gene mutations on severity and response to therapy during retreatment of advanced chronic hepatitis C in the HALT-C Trial. (Publication 17 from the HALT-C Trial Group). Gastroenterology 131: 1440-1451, 2006 [PMID: 17101320]. [Editorial comment at Gastroenterology 131: 1635-1638, 2006.]

Shan Y, Lambrecht RW, and Bonkovsky HL. Role of Bach1 and Nrf2 in up-regulation of the heme oxygenase-1 gene by cobalt protoporphyrin. FASEB Jl, 20: 2651-2653, 2006. [PMID 17065227]

Fontana RJ, Sanyal AJ, Mehta S, Doherty MC, neuschwanter-Tetri BA, Everson GT, Kahn JA, Malet PF, Sheikh MY, Chung RT, Ghany MG, Gretch DR, and the HALT-C Trial Group. Portal hypertensive gastropathy in chronic hepatitis C patients with bridging fibrosis and compensated cirrhosis: results from the HALT-C Trial. Am J Gastroenterol 101: 983-992, 2006. [PMID 16573786]

Sanyal AJ, Fontana RJ, Di Bisceglie AM, Everhart JE, Doherty MC, Everson GT, Donovan JA, Malet PF, Mehta S, Sheikh MY, Reid AE, Ghany MG, Gretch DR, HALT-C Trial Group. The prevalence and risk factors associated with esophageal varices in subjects with hepatitis C and advanced fibrosis. Gastrointest Endosc 64: 855—864, 2006. [PMID: 17140886]

Lambrecht RW, Thapar M, and Bonkovsky HL. Genetic aspects of porphyria cutanea tarda. Semin Liver Dis. 27: 99-108, 2007. [PMID: 17295179]

Lok ASF, Everhart JE, Chung RT, Padmanabhan L, Greenson JK, Shiffman ML, Everson GT, Lindsay KL, Bonkovsky HL, Di Bisceglie AM, Lee WM, Morgan TR, Ghany MG, Morishima C, and the HALT-C Trial Group. Hepatic steatosis in hepatitis C: comparison of diabetic and non-diabetic patients in the hepatitis C antiviral long-term treatment against cirrhosis trial (Publication # 13 from the HALT-C Trial Group). Clin Gastroenterol Hepatol 5: 245-254, 2007. [PMID: 17296533]

Immenschuh S, Shan Y, Kroll H, Santoso S, Woessmann W, Tegtmeyer KF, Bein G, and Bonkovsky HL. Marked hyperbilirubinemia associated with the heme oxygenase-1 gene promoter microsatellite polymorphism in a boy with autoimmune hemolytic anemia. Pediatrics. 119:e764-7, 2007, Epub 2007 Feb 26. [PMID: 17325212]

Bonkovsky HL, Snow KK, Malet PF, Back-Madruga C, Shiffman ML, Everson GT, Fontana RJ, Di Bisceglie AM, Morgan TR, Dienstag JL, Ghany MG, Morishima C, and the HALT-C Trial Group. Health-related quality of life in patients with chronic hepatitis C and advanced fibrosis. (Publication # 14 from the HALT-C Trial Group) Journal of Hepatology, 46: 420-431, 2007.

Ghaziani T, Alavian SM, Zali MR, Shahraz S, Agah M, Jensen KP, Ansari S, Sendi H, Lambrecht RW, Covault J, and Bonkovsky HL. Serum measures of iron status and HFE gene mutations in patients with hepatitis B virus infection. Hepatology Research 37: 172-178, 2007.

Everson GT, Hoefs JC, Malet P, Seeff LB, Bonkovsky HL, Wright E, and the HALT-C Trial Group. Impact of disease severity on clinical management and outcome of antiviral therapy in patients with chronic hepatitis C lessons from the HALT-C Trial. (Publication 19 from the HALT-C Trial Group) Hepatology 44: 1675-1684, 2006. [PMID: 17133499]

Shiffman ML, Ghany MG, Morgan TR, Wright EC, Everson GT, Lindsay KL, Lok ASF, Bonkovsky HL, Di Bisceglie AM, Lee WM, Dienstag JL, Morishima C, Everhart JE, and the HALT-C Trial Group. Impact of reducing peginterferon alfa-2a and ribavirin dose during retreatment in patients with chronic hepatitis C. (Publication # 20 from the HALT-C Trial Group). Gastroenterology, 132: 103-112, 2007. [PMID: 17241864]

Shiffman ML, Suter F, Bacon BR, Nelson D, Harley H, Sola R, Shafran SD, Barange K, Lin A, Soman A, Zeuzem S, and the ACCELERATE Investigators. Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3. New England Journal of Medicine 357:124-134, 2007. [PMID: 17625124] [Editorial comment at NEJM 352: 176-178, 2007]

Bielauskas LA, Back-Madruga C, Lindsay KL, Wright EC, Kronfol Z, Lok ASF, Fontana RJ, HALT-C Trial Group. Cognitive reserve and neuropsychological functioning in patients infected with hepatitis C. (Paper # 21 from the HALT-C Trial Group). J Intl Neuropsychol Soc 13: 687-692, 2007. [PMID: 17521478]

Fontana RJ, Bielauskas LA, Lindsay KL, Back-Madruga C, Wright EC, Snow KK, Lok ASF, Kronfol Z, Padmanabhan L, HALT-C Trial Group. Cognitive function does not worsen during pegylated interferon and ribavirin retreatment of chronic hepatitis C. (Publication # 22 from the HALT-C Trial Group). Hepatology 45: 1154-1163, 2007. [PMID: 17465000]

Everson GT, Martucci MA, Shiffman ML, Sterling RK, Morgan TR, Hoefs JC, HALT-C Trial Group. Portal-systemic shunting in patients with fibrosis or cirrhosis due to chronic hepatitis C: the minimal model for measuring cholate shunt clearances and shunt. (Paper # 23 from the HALT-C Trial Group). Alimentary Pharmacol & Therap 26: 401-410, 2007. [PMID: 17635375]

Hou W, Shan Y, Zheng J, Lambrecht RW, Donohue SE, and Bonkovsky HL. Zinc mesoporphyrin induces rapid and marked degradation of the transcription factor Bach1 and up-regulates HO-1. Biochimica et Biophysica Acta, 1779: 195-203, 2008. [PMID: 18325350]

Venkataraman K, Lee YM, Michaud J, Ai Y, Thangada S, Ai Y, Bonkovsky HL, Parikh NS, Habrukowich C, and Hla T. Vascular endothelium as a contributor of plasma sphingosine 1-phosphate. Circulation Research 102: 669-676, 2008. [PMID 18258856]

Desai TK, Jamil LH, Balasubramanian M, Koff RS, and Bonkovsky HL. Phlebotomy improves therapeutic response to interferon in patients with chronic hepatitis C: a meta-analysis of six prospective randomized controlled trials. Digestive Diseases and Sciences 53:815-822, 2008. [PMID 17846887]

Shan Y, Zheng J-Y, Lambrecht RW, Bonkovsky HL. Reciprocal effects of micro-RNA-122 on expression of heme oxygenase-1 and hepatitis C virus genes in human hepatocytes. Gastroenterology 133: 1166-1174, 2007. [PMID 17919492]

Seeff LB, Curto TM, Szabo G, Everson GT, Bonkovsky HL, Dienstag JL, Shiffman ML, Lindsay KL, Lok ASF, Di Bisceglie AM, Lee WM, Ghany MG, HALT-C Trial Group. Herbal product use by persons enrolled in the Hepatitis C Antiviral Long-Term Treatment Against Cirrhosis (HALT-C) Trial. (Paper # 27 from the HALT-C Trial Group). Hepatology 47: 605-612, 2008. [PMID: 18157835]

Bonkovsky HL, Siao P, Roig Z, Hedley-Whyte ET, Flotte TJ. Case 20-2008. A 57-year-old woman with abdominal pain and weakness after gastric bypass surgery. Case Records of the Massachusetts General Hospital. New England Journal of Medicine, 358: 2813-2825, 2008. [PMID: 18579817]

Fontana RM, Goodman ZD, Dienstag JL, Bonkovsky HL, Naishadham D, Sterling RK, Su GL, Ghosh M, Wright EL, and the HALT-C Trial Group. Relationship of serum fibrosis markers with liver fibrosis stage and collagen content in patients with advanced chronic hepatitis C. (Paper # 26 from the HALT-C Trial Group). Hepatology 47: 789—798, 2008. [PMID: 18175357] [Comment in Hepatology 48: 688-689; author reply 689-690, 2008]

Everson GT, Shiffman ML, Morgan TR, Hoefs JC, Sterling RK, Wagner DA, Kulig CC, Curto TM, Wright EC, HALT-C Trial Group. The spectrum of hepatic functional impairment in compensated chronic hepatitis C: results from the HALT-C Trial. (Publication # 18 from the HALT-C Trial Group). Aliment Pharmcacol Therap 27: 798-809, 2008. [PMID: 18266997]

Lindsay KL, Morishima C, Wright EC, Dienstag JL, Shiffman ML, Everson GT, Lok ASF, Bonkovsky HL, Lee WM, Morgan TR, Ghany MG, and the HALT-C Trial Group. Blunted cytopenias and weight loss: new correlates of virologic null response to retreatment of chronic hepatitis C. (Paper # 15 from the HALT-C Trial Group). Clin Gastroenterol Hepatol 6: 234-241, 2008. [PMID: 18237873]

Di Bisceglie AM, Shiffman ML, Lindsay KL, Everson GT, Lindsay, KL, Everhart JE, Wright EC, Lee WM, Bonkovsky HL, Morgan TR, Dienstag JL, Ghany MG, Morishima C, Snow KK, for the HALT-C Trial Group. Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon. (Publication # 29 from the HALT-C Trial Group) New Engl J Med 359: 2429-2441, 2008. [PMID 19052125]

Zheng J, Tian Q, Hou W, Watts JA, Schrum LW, Bonkovsky HL. Tissue-specific expression of ALA synthase-1 and heme oxygenase-1 and their expression in livers of rats chronically exposed to ethanol. FEBS Letters 528: 1829--1834, 2008. [PMID 18472004]

Zheng J-Y, Shan Y, Lambrecht RW, Donohue SE, Bonkovsky HL. Differential regulation of human ALAS1 mRNA and protein levels by heme and cobalt protoporphyrin. Molecular and Cellular Biochemistry 319: 153-161, 2008 [PMID 18719978].

Bonkovsky HL, Tice AD, Yapp RG, Bodenheimer HC Jr., Monto A, Rossi SJ, Sulkowski MS. Efficacy and safety of peginterferon alfa-2a/ribavirin in methadone maintenance patients: randomized comparison of direct observed therapy and self-administration. Amer J Gastroenterology 103: 1-9, 2008. [PMID: 18684176].

Thapar M, Bonkovsky HL. The diagnosis and management of erythropoietic protoporphyria. Gastroenterology & Hepatology 4: 561-566, 2008.

Morishima C, Morgan TR, Everhart JE, Wright EC, Apodaca MC, Gretch DR, Shiffman ML, Everson GT, Lindsay KL, Lee WM, Lok ASF, Dienstag JL, Ghany MG, Curto TM, and the HALT-C Trial Group. Interpretation of positive transcription-mediated amplification test results from polymerase chain reaction-negative samples obtained during and after treatment of chronic hepatitis C. (Publication #28 from the HALT-C Trial Group). Hepatology 48: 1412-1419, 2008. [PMID: 18816437].

Morgan TR, Lambrecht RW, Bonkovsky HL, Chung RT, Naishadham D, Sterling RK, Fontana RJ, Lee WM, Ghany MG, Wright EC, O’Brien TR, and the HALT-C Trial Group. DNA polymorphisms and response to treatment in patients with chronic hepatitis C: results from the HALT-C Trial. (Publication # 30 from the HALT-C Trial Group). J Hepatology 49: 548-556, 2008. [PMID: 18619701].

Rochon J, Protiva P, Seeff LB, Fontana RJ, Liangpunsakul S, Hayashi PH, Davern T, McHutchison JG, and the Drug-Induced Liver Injury network (DILIN). The reliability of the Roussel Uclaf causality assessment method for assessing causality in drug-induced liver injury. [Publication #1 from the US DILIN] Hepatology, 48: 1175-1183, 2008. [PMID 18798340]

Phatak PD, Bonkovsky HL, Kowdley KV. Hereditary hemochromatosis: time for targeted screening. Annals of Internal Medicine 149: 270-272, 2008. [PMID: 18711158]

Bonifaz V, Shan Y, Lambrecht RW, Donohue SE, Moschenross D, Bonkovsky HL. Effects of silymarin on hepatitis C virus and haem oxygenase-1 gene expression in human hepatoma cells. Liver Intl 29: 366-373, 2009. [PMID 18694403]

Chalasani N, Fontana RJ, Bonkovsky HL, Watkins PB, SerranoJ, Yang H, Rochon J, for the DILIN Study Group. Causes, clinical features and outcomes from a prospective study of drug-induced liver injury in the United States. Gastroenterology 135: 1924--1934, 2008. [Publication #3 from the US DILIN] [PMID: 18955056]. [Editorial comment by Rochling FA, Zetterman RK. Do Hepatotoxicity registries have a role in health care?, Gastroenterology 135: 1847-850, 2008]

Lok AS, Seeff LB, Morgan TR, Di Bisceglie AM, Sterling RK, Curto TM, Everson GT, Lindsay KL, Lee WM, Bonkovsky HL, Dienstag JL, Ghany MG, Morishima C, Goodman ZD, and the HALT-C Trial Group. Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease. Gastroenterology 2009; 136:138-148. [PMID: 18848939]

Fontana RJ, Watkins PB, Bonkovsky HL, Chalasani N, Davern T, Serrano J, Rochon J, for the DILIN Study Group. Rationale, design and conduct of the Drug-Induced Liver Injury Network (DILIN) prospective study. Drug Safety, 32: 55-68, 2009 [PMID 19132805]. [Publication #2 from the US DILIN]

Everson GT, Shiffman ML, Morgan TR, Hoefs JC, Sterling RK, Wagner DA, DeSanto JL, Curto TM, Wright EC, and the HALT-C Trial Group. Hepatic improvement after sustained virologic response as measured by quantitative tests of liver function: results from the HALT-C Trial. [Publication #33 from the HALT-C Trial Group] Submitted 2008.

Fontana RJ, Bonkovsky HL, Naishadham D, Dienstag JL, Sterling RK, Lok ASF, Su GL, and the HALT-C Trial Group. Serum fibrosis markers during pegylated interferon and ribavirin treatment of patients with chronic hepatitis C: a report from the HALT-C Trial. [Publication #36 from the HALT-C Trial Group] Clin Gastroent & Hepatol 7: 219—226, 2009 [PMID: 19068241].

Lok ASF, Everhart JE, Chung RT, Kim H-Y, Everson G, Hoefs J, Greenson JK, Sterling RK, Lindsay KL, Lee, WM, Di Bisceglie AM, Bonkovsky HL, Ghany MG, Morishima C and the HALT-C Trial Group. Evolution of hepatic steatosis in patients with advanced hepatitis C: results from the HALT-C Trial. [Publication #37 from the HALT-C Trial Group] Hepatology, 49: 1828-1837, 2009 [PMID: 19291787].

Panov A, Schonfeld P, Dikalov S, Hemendinger R, Bonkovsky Hl, Brooks BR. The neuromediator glutamate, through specific substrate interactions, enhances mitochondrial ATP production and ROS generation in nonsynaptic brain mitochondria. J Biol Chem 284: 14,448-56, 2009 [PMID: 19304986].

Welzel TM, Morgan TR, Bonkovsky HL, Naishadham D, Pfeiffer RM, Wright EC, Hutchinson AA, Crenshaw A, Bashirova A, Carrington M, Dotrang M, Sterling RK, Lindsay KL, Fontana RJ, Lee WM, Di Bisceglie AM, Ghany MG, Gretch DR, Chancok SJ, Chung RT, O’Brien TR, HALT-C Trial Group. Variants in interferon-alpha pathway genes and response to pegylated interferon-alpha 2a plus ribavirin for treatment of chronic hepatitis C virus infection in the hepatitis C antiviral long-term treatment against cirrhosis trial. Hepatology 49: 1847-1858, 2009 [PMID 19434718].

Pierucci-Lagha A, Covault J, Bonkovsky HL, Feinn R, Abreu C, Sterling RK, Fontana RJ, Kranzler HR, and the HALT-C Trial Group.. A functional serotonin transporter gene polymorphism and depressive effects associated with interferon-alpha treatment. [Publication #25 from the HALT-C Trial Group] Psychosomatics, 2009, in press.

Bell MC, Robuck PR, Wright EC, Mihova MS, Hofmann C, De Santo JL, Milstein SL, Richtmyer PA, Shelton JL, Cormier M, King DL, Park CJ, Molchen WA, Park Y, Kelley M, and the HALT-C Trial Group. Automating serious adverse event (SAE) reporting in the hepatitis C antiviral long-term treatment against cirrhosis (HALT-C) trial. [Publication # 31 from the HALT-C Trial Group], Clinical Trials, 2009, in press.

Rustgi VK, Lee WM, Lawitz E, Gordon SC, Afdhal N, Poordad F, Bonkovsky HL, Bengtsson L, Chandorkar G, Harding M, McNair L, Aalyson M, Alam J, Kauffman R, Gharakhanian S, McHutchison JG, on behalf of the MErimepodib TRiple cOmbination (METRO) Study Group. Merimepodib, pegylated interferon, and ribavirin in genotype-1 chronic hepatitis C pegylated interferon and ribavirin non-responders: a randomized study. Hepatology, 2009, in press.

Freedman ND, Everhart JE, Lindsay KL, Ghany MG, Curto TM, Abnet CC, Sinha R, Shiffman M, Everson GT, Lee WM, Di Bisceglie AM, Bonkovsk;y HL, Morgan T, Dienstag JL, Morishima C, and the HALT-C Trial Group. Coffee intake is associated with lower rates of liver disease progression in chronic hepatitis C: findings from the hepatitis C antiviral long-term treatment against cirrhosis (HALT-C) trial. [Publication # xx from the HALT-C Trial Group] Hepatology, 2009, in press.

Ghany MG, Lok ASF, Everhart JE, Everson GT, Lee WM, , Curto TM, Wright EC, Stoddard AM, Sterling RK, Di Bisceglie AM, Bonkovsky HL, Morishima C, Morgan TR, Dienstag JL, for the HALT-C Trial Group. Predicting clinical outcome and progression to cirrhosis based on standard laboratory tests: analysis of the hepatitis C antiviral long-term treatment against cirrhosis (HALT-C) trial cohort. [Publication # 40 from the HALT-C Trial Group]. Gastroenterology, 2009, in press.

Everhart JE, Lok AS, Kim H-Y, Morgan TR, Lindsay KL, Chung RT, Bonkovsky HL, Ghany MG, and the HALT-C Trial Group. Weight related effects on disease progression in the hepatitis C antiviral long-term treatment against cirrhosis trial. [Publication # 39 from the HALT-C Trial Group] Gastroenterology 137: 549-557, 2009.

Sendi H, Mehrabv-Mohseni M, Shahraz S, Norder H, Seyed-Moayed A, Noorinayer B, Zali MR, Pumpens P, Bonkovsky HL, Magnius LO. CTL escape mutations of core protein are more frequent in strains of HBeAg negative patients with low levels of HBV DNA. J Clin Virol xxx: xxx-xxx, 2009.

Rockey DC, Seeff LB, Rochon J, Freston J, Chalasani N, Bonacini M, Fontana RJ, Hayashi PH, for the Drug-Induced Liver Injury Network. The drug-induced liver injury network causality assessment method (DILICAM): Comparison with RUCAM [Publication #4 from the US DILIN]. Hepatology, in press, 2009.

Hou W, Tian Q, Zheng J, Bonkovsky HL. MicroRNA-196 represses Bach1 expression in human hepatoma cells stably expressing hepatitis C viral proteins. Hepatology, 2009, in press.

Hou W, Tian Q, Zheng J, Bonkovsky HL. Zinc mesoporphyrin induces rapid proteasome-mediated degradation of hepatitis C nonstructural 5A protein in human hepatoma cells. Gastroenterology, 2009, in press [Gastro-D-09-00234].

Hou W, Rossi L, Shan Y, Zheng J, Lambrecht RW, Bonkovsky HL. Iron increases heme oxygenase-1 (HMOX1) and decreases expression of hepatitis C virus (HCV) in HCV-expressing human hepatoma cells. World J Gastroent, 2009, in press [wjg/2009/020393]

Everhart JE, Wright EC, Goodman ZD, Dienstag JL, Hoefs J, Kleiner D, Ghany M, Mills A, Nash A, Govindarajan S, Rogers T, Greenson J, Brunt E, Bonkovsky HL, Morishima C, Litman H, and the HALT-C Trial Group. Prognostic value of Ishak fibrosis stage: findings from the HALT-C Trial. [Publication #47 from the HALT-C Trial Group] Hepatology, 2009, in press.

Zhang L, Wang G, Hou, W, Li P, Dulin A, Bonkovsky HL. Contemporary clinical research of traditional Chinese medicines for chronic hepatitis B in China; an analytical review. Hepatology 51: 690-698, 2010. [PMID 20101751].

Lok ASF, Everhart JE, Chung RT, Padmanabhan L, Greenson JK, Shiffman ML, Everson GT, Lindsay KL, Bonkovsky HL, Di Bisceglie AM, Lee WM, Morgan TR, Ghany MG, Morishima C, and the HALT-C Trial Group. Hepatic steatosis in hepatitis C: comparison of diabetic and non-diabetic patients in the hepatitis C antiviral long-term treatment against cirrhosis trial (Publication # 13 from the HALT-C Trial Group). Clin Gastroenterol Hepatol 5: 245-254, 2007. [PMID: 17296533]

Fontana RJ, Sanyal AJ, Ghany MG, Lee WM, Reid AE, Naishadham D, Everson GT, Kahn JA, Di Bisceglie AM, Szabo G, Morgan TR, Everhart JE, and the HALT-C Trial Group. Development and progression of gastroesophageal varices in patients with chronic hepatitis C monitored in a prospective multi-center study. [Publication #48 from the HALT-C Trial Group]. Gastroenterology, in press, 2010.

Narang TK, Sendi H, Scobey M, Bonkovsky HL. Iron and hepatitis C. Current Hepatitis Reports, 2010, in press.